PT Bifarma Adiluhung
Address: Kalbe Business Innovation Center Industrial Area,, Pulogadung Street No.23, RW.9, Jatinegara, Cakung,, East Jakarta, 13930About Us
Established in 1966, Kalbe has gone a long way from a humble operation that started in a garage to become the leading pharmaceutical company in Indonesia. Growing both organically and through mergers & acquisitions, Kalbe expands its business interests and transforms itself to become a provider of an integrated healthcare solution through its 4 business divisions: the Prescription Pharmaceutical Division, Consumer Health Division, Nutritionals Division and Distribution and Logistics Division. Kalbe Farma has established robust research and development activities in leading edge generic drug formulation and continuous development of innovative consumer and nutritional products. Through strategic alliances with international partners, Kalbe has also started to support several successful research and development ventures working on cancer drugs, stem cells and biotechnology research. This business is operating in the biopharma division. Biopharma division as one of the strategic business units was developed in 1995, is a leading biotechnology company aiming at providing clinically proven and quality guaranteed biopharmaceutical generics as well as developing innovative biopharmaceutical that requires scientific and clinical development in the global market. Biopharma Strategic Business Unit has 7 subsidiaries and a research center. PT. Bifarma Adiluhung is a holding company who is serving the entire Biopharma entities and the new business incubator in the Biopharma sector. Biopharma will play important roles in future health and will be a part of the world from what we have now. In essence, we are on a mission to improve health for a better life by preventive, promotive, and predictive treatment. We want you to be part of our journey, so let’s build a healthy nation with us. Can’t wait to see you grow together with Bifarma Adiluhung!
Sectors
- Proprietary Research & Manufacture
- Generic Formulations
- Contract Manufacturing
- Collaborations & Partnerships- R&D
- Collaborations & Partnerships-Manufacture
Categories
- Biotechnology
- Biologics
- Cell Therapy
- Cell Therapy Products
- Regenerative Medicine
- Oncology Products
- Anti-Cancer Products
News
Regenic And GC CELL Officialy Launch Strategic Partnership In Cancer Therapy
PT Kalbe Farma Tbk (Kalbe) through its subsidiary PT Bifarma Adiluhung (Bifarma), which oversees the Regenic brand, has officially launched a strategic partnership with the global biotechnology company from South Korea, GC Cell.
The strategic partnership between Regenic and GC Cell aims to facilitate the introduction of Immuncell-LC in Indonesia. Immuncell-LC is an innovative cell therapy using autologous T cell therapy and has obtained approval for liver cancer treatment in Korea. Furthermore, the agreement between Regenic and GC Cell also includes technology transfer and collaboration on the development of Natural Killer (NK) Cells therapy pipeline, which has scientifically proven efficacy in killing cancer cells.
Source: The Partnership Tree | https://www.pharmaservicesdirectory.com